Gradalis
Dallas, Texas, United States · Biotechnology, Health Care, Therapeutics
Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company’s proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and is applicable to multiple cancer types.
Key facts
- Headquarters
- Dallas, Texas, United States
- Employees
- 25
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- www.gradalisinc.com
- Company page
Recent activity at Gradalis
- : Gradalis
- : Gradalis, Inc. Announces FDA Designation for Vigil® (Gemogenovatucel-T) as a Personalized Immunotherapy for Advanced Ovarian Cancer
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Gradalis funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2025 | Venture | $12.7M |
Leadership
- Rebecca (Winship) Lutz, Vice President
- Ernie Bognar, Chief Operating Officer
Verified email and direct lines for Gradalis’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Gradalis files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to Gradalis
- Tenpoint Therapeutics · Biotechnology, Health Care, Therapeutics
- Navigator Medicines · Biotechnology, Health Care, Therapeutics
- Paradigm Biopharmaceuticals · Biotechnology, Health Care, Therapeutics
- Anavo Therapeutics · Biotechnology, Health Care, Therapeutics
- Immunocine Cancer Center · Biotechnology, Health Care, Therapeutics
About Gradalis: questions and answers
What does Gradalis do?
Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company’s proprietary bi-shRNA therapy platform, which has been proven in its clinical studies, can be utilized to silence a broad range of genes and is applicable to multiple cancer types.
Where is Gradalis headquartered?
Gradalis is headquartered in Dallas, Texas, United States.
How many employees does Gradalis have?
Gradalis has about 25 employees.
Has Gradalis raised funding?
Yes. Fundz has recorded 1 funding event for Gradalis. The most recent, $12.7M, was in Jun 2025.
Who leads Gradalis?
Rebecca (Winship) Lutz is a Vice President at Gradalis.
What is the latest news on Gradalis?
On Jun 5, 2025, Gradalis
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy